Rivaroxaban for Antiphospholipid Antibody Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Antiphospholipid Antibody Syndrome
Interventions
DRUG

Rivaroxaban

Trial Locations (6)

T6G 2P4

University of Alberta Hospital, Edmonton

B3H 2Y9

Queen Elizabeth II Hospital, Halifax

L8L 2X2

Hamilton General Hospital, Hamilton

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

K1H 8L6

The Ottawa Hospital, Ottawa

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Hamilton Health Sciences Corporation

OTHER

collaborator

Jewish General Hospital

OTHER

collaborator

University of Alberta

OTHER

collaborator

The Ottawa Hospital

OTHER

collaborator

Queen Elizabeth II Health Sciences Centre

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT02116036 - Rivaroxaban for Antiphospholipid Antibody Syndrome | Biotech Hunter | Biotech Hunter